The University of Pittsburgh has registered a small clinical trial that will ask whether exercise during chemotherapy can change what happens around an ovarian tumor, and whether that might help the treatment work. The study, called IMPROVE-Ovarian, was posted on the US public trial registry on November 12, 2026, and is not yet recruiting patients1. It has no results.
What happened
The registry record lists the University of Pittsburgh as the sponsor and an estimated 20 participants1. The trial is set to start on December 1, 2026, and the date for collecting its main data is August 31, 20271. It is listed for women with high-grade serous ovarian cancer and related forms of ovarian cancer1.
The study has two stated goals. The first is to find out whether an exercise program delivered by telehealth (coaching over video or phone) is feasible and acceptable to women during their chemotherapy1. The second is to measure how exercise affects immune function, inflammation and treatment response1. The program includes both resistance training, such as strength work, and aerobic training, such as walking or cycling1.
The chemotherapy in question is the treatment given early on, which the registry calls neoadjuvant chemotherapy1. The full title of the study refers to “primary chemotherapy response”1.
How the trial is set up
The registry lists two approaches being studied: exercise, and usual care1. Both are labeled as behavioral, meaning they involve what people do rather than a drug or device1. The trial has no drug phase listed, which is typical for a study that does not test a medicine1.
The main measurements are not about the cancer itself. They are:
- Acceptability: whether women find the program reasonable to do1.
- Adherence: whether they stick with it1.
- Feasibility: whether it can be delivered as planned1.
Each is tracked from enrollment until the end of the study, roughly three to four months per person1. Changes in immune function, inflammation and treatment response are the second aim1.
Why the area around the tumor matters
The trial’s full name refers to the “tumor microenvironment”1. That is the neighborhood around cancer cells: a moving network of signaling molecules, growth factors, sticky proteins, blood and lymph vessels, and cells that travel in and out of the tumor2. Fibers in this area, known as the extracellular matrix, can be laid down abnormally and make tumors stiffer2.
For decades, cancer research focused mostly on the genes of the cancer cell itself, and much less on this surrounding tissue2. A 2018 study led by Oliver Pearce of Barts Cancer Institute in London looked at tissue samples from spread high-grade serous ovarian cancer, which CancerNetwork described as the most common and aggressive subtype of the disease2. The team found a pattern across 22 genes linked to the tissue scaffolding, which they called a “matrix index,” and it was associated with shorter survival in ovarian cancer and in 12 other cancer types2.
Commenting on that work, Ernst Lengyel of the University of Chicago wrote:
Only by understanding both the cancer cells and the supporting tumor cells will we be able to understand and successfully target this deadly disease.
2 That study did not involve exercise. It shows why researchers now look at a tumor’s surroundings, not only the cancer cells, when they ask how a treatment might be helped.
What earlier research shows
Exercise during cancer care was once discouraged. Around 2000, “rest is best” was the common view for almost all cancer patients, according to Pitt Med magazine, the University of Pittsburgh’s medical school publication3. The magazine reports that a large body of evidence has since linked regular physical activity to better outcomes, including survival, physical function, sleep, fatigue and mood, across cancer types3.
The magazine pointed to a trial in the New England Journal of Medicine of 889 colon cancer patients who did either a supervised exercise program or a health education program for three years after chemotherapy3. People in the exercise group had markedly better survival without the disease returning, and better overall survival3. That was a different cancer, and the exercise came after chemotherapy rather than during it.
Ovarian cancer has its own exercise trial. In Australia, a study called ECHO, led by Sandra Hayes, tested an exercise program during first chemotherapy for ovarian cancer, compared in a randomized, controlled design4. The program lasted about 18 weeks, matching the length of chemotherapy4. The World Cancer Research Fund reported that the program was proving safe, with no serious exercise-related harms, and that about 10% of women had withdrawn4. Funding secured in 2020 allowed the team to follow a total of 500 women, making ECHO one of only four trials worldwide large enough to test whether exercise affects how long patients live before the cancer grows again4.
Scientists still do not know exactly how exercise might affect cancer. A Pitt immunologist, Marlies Meisel, told the magazine that “the mechanism is really poorly understood”3. Her lab reported in the journal Cell that mice with melanoma, a skin cancer, that exercised for four weeks had smaller tumors and lived longer than inactive mice, and that the effect depended on gut bacteria3. That was a mouse study and did not involve ovarian cancer.
What this trial cannot show
IMPROVE-Ovarian is small and early. With an estimated 20 women, it is designed mainly to answer practical questions: will women take part, will they keep exercising, and can the program be delivered by telehealth during chemotherapy1. Those are the main outcomes listed1.
Measures of immune function, inflammation and treatment response are a secondary aim1. In a group this size, any differences found would be hard to separate from chance. The trial will not show whether exercise helps women live longer or keeps ovarian cancer from coming back. The registry does not say how participants will be assigned to exercise or usual care, or which specific immune or tumor measures will be used1.
Who is behind it
The University of Pittsburgh is the sponsor on the registry record1. The record does not list a drug company or commercial funder, and no product is being tested1.
The university already runs an exercise program for cancer patients. UPMC Hillman Cancer Center’s program, Moving Through Cancer, is directed by Kathryn Schmitz, the center’s deputy director, and uses exercise professionals who guide patients through telehealth sessions3. The program recommends both aerobic and resistance exercise, scaled to each patient’s condition3. Pitt Med magazine reported that Schmitz and Meisel were planning a study to move findings from mice to humans3. The registry record shared with Biohack does not name the trial’s investigators, so it is not clear from these sources whether IMPROVE-Ovarian is that study.
Schmitz has argued that exercise lacks the business backing that drugs have. In a commentary titled “If exercise were a pill, we’d all prescribe it to patients with cancer. But it’s not,” she pointed to the missing support systems that patients need to exercise during treatment3.
What to watch next
- Recruitment: the registry lists a December 1, 2026 start; the status should change once women begin enrolling1.
- Main data: the primary completion date is August 31, 20271. Results have not been posted.
- What gets measured: whether the team reports specific immune or tumor changes alongside the feasibility findings.
- Larger trials: results from Australia’s ECHO trial, with its planned 500 women, may give a clearer answer on survival in ovarian cancer4.
For now, IMPROVE-Ovarian is a plan on a public registry. It asks a narrow first question about whether coached exercise fits into ovarian cancer chemotherapy, and it may give early hints about what exercise does around a tumor1.
